Ceva welcomed more than 200 global delegates to their New Technology Vaccine Symposium on April 9 in Miami, Fla. Ceva held its first Symposium two years ago to address the expectations regarding new technology vaccines now available to the poultry industry. This second symposium is addressing the experiences to date from the worldwide usage of vector vaccines. The program is about innovation, new developments for the future, new products for the market looking out to 2020 and working with all parts of the poultry industry to bring new vaccines to the market.
With hatcheries expected to continue consolidating and becoming larger in capacity, their higher operational costs and focus on labor will drive the growth of broiler vaccination worldwide from 65 percent today to more than 75 percent in the next 3-5 years. The In-ovo system is expected to become the standard in the years ahead, a result of continuing equipment technology and vaccine advancements enabling smaller producers to receive a positive return on their investment.
Arnaud Bourgeois, biology business unit director Ceva Group, France, opened the symposium and welcomed the international delegates representing the global poultry industry. Dr. Sylvain Comte, poultry corporate marketing director Ceva Group, France discussed the global evolution of new technology vaccines use in the hatchery. Dr. Moto Esaki, manager vaccine research, Ceva Japan provided perspectives in vector vaccine development. Marleen Boerjan, scientific director Pas Reform gave an update on the importance of Uniform embryonic development - in the hen and the incubator. Carlos Gonzalez Alonso, global technical and marketing manager for vaccination equipment and services, Ceva Group France updated the delegates on vaccination equipment - status the future expectation followed by a thorough question and answer roundtable to close the first day session.
The Symposium Scientific Program will continue through April 11 with continued updates on the worldwide usage of new technology vaccines, scientific knowledge exchange, and practical presentations from producer experiences worldwide.
With hatcheries expected to continue consolidating and becoming larger in capacity, their higher operational costs and focus on labor will drive the growth of broiler vaccination worldwide from 65 percent today to more than 75 percent in the next 3-5 years. The In-ovo system is expected to become the standard in the years ahead, a result of continuing equipment technology and vaccine advancements enabling smaller producers to receive a positive return on their investment.
Arnaud Bourgeois, biology business unit director Ceva Group, France, opened the symposium and welcomed the international delegates representing the global poultry industry. Dr. Sylvain Comte, poultry corporate marketing director Ceva Group, France discussed the global evolution of new technology vaccines use in the hatchery. Dr. Moto Esaki, manager vaccine research, Ceva Japan provided perspectives in vector vaccine development. Marleen Boerjan, scientific director Pas Reform gave an update on the importance of Uniform embryonic development - in the hen and the incubator. Carlos Gonzalez Alonso, global technical and marketing manager for vaccination equipment and services, Ceva Group France updated the delegates on vaccination equipment - status the future expectation followed by a thorough question and answer roundtable to close the first day session.
The Symposium Scientific Program will continue through April 11 with continued updates on the worldwide usage of new technology vaccines, scientific knowledge exchange, and practical presentations from producer experiences worldwide.
No comments:
Post a Comment